1408238-37-8

Basic information

• Product Name: Dabigatran Impurity p
• Synonyms: 3-(2-(((4-(((hexyloxy)carbonyl)carbamoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid;BIBR1155
• CAS NO: 1408238-37-8
• Molecular Formula: C₃₂H₃₆N₆O₆
• Molecular Weight: 600.66484
• Mol File: 1408238-37-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 4.17±0.10(Predicted)
• CAS DataBase Reference: Dabigatran Impurity p(CAS DataBase Reference)
• NIST Chemistry Reference: Dabigatran Impurity p(1408238-37-8)
• EPA Substance Registry System: Dabigatran Impurity p(1408238-37-8)

Safety Data

• Hazardous Substances Data: 1408238-37-8(Hazardous Substances Data)

Usage

Description

Dabigatran Impurity p, also known as N-[[2-[[[4-[[[(Hexyloxy)carbonyl]amino]carbonyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-alanine, is an impurity found in Dabigatran Etexilate Mesylate (D100150). Dabigatran Etexilate Mesylate is a nonpeptide, direct thrombin inhibitor used in the medical field for various applications.

Uses

Used in Pharmaceutical Industry:
Dabigatran Impurity p is used as an impurity in the production of Dabigatran Etexilate Mesylate, a direct thrombin inhibitor. The presence of this impurity is crucial for the development and improvement of the drug's efficacy and safety profile. It helps researchers understand the potential side effects and interactions of the drug, allowing for better drug design and formulation.
Dabigatran Impurity p is used as a research tool for studying the mechanism of action, pharmacokinetics, and pharmacodynamics of Dabigatran Etexilate Mesylate. This knowledge aids in optimizing the drug's therapeutic potential and minimizing adverse effects.
Additionally, Dabigatran Impurity p can be used in the development of novel drug delivery systems, aiming to improve the bioavailability and therapeutic outcomes of Dabigatran Etexilate Mesylate. This may involve the use of various organic and metallic nanoparticles as carriers for the impurity, enhancing its delivery and effectiveness in treating conditions related to thrombin inhibition.

Upstream product

• 42288-26-6 (4-cyanophenyl)glycine 
• 873-74-5 4-Aminobenzonitrile 
• 429658-95-7 3-({2-[(4-carbamimidoylphenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid ethyl ester 
• 211915-06-9 dabigatran etexilate 
• 1415506-19-2 3-[[[2-[[[4-[amino[[[(hexyloxy)carbonyl]amino]methyl]]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propionic acid 

Relevant articles and documents

DABIGATRAN ETEXILATE AND RELATED SUBSTANCES, PROCESSES AND COMPOSITIONS, AND USE OF THE SUBSTANCES AS REFERENCE STANDARDS AND MARKERS

The present invention relates to dabigatran etexilate and related substances and use of the substances as reference standards and markers. There are also provided processes of detecting the substances in samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof, and also for analyzing the purity of samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof.There are still further provided processes of preparing dabigatran etexilate and related substances, and pharmaceutical compositions containing the same.